For established research programs, it remains a workhorse molecule that continues to produce publishable results
So an advertising case can be brought against the whole business, not just one doctor
Recently, belimumab and anifrolumab have shown clinical benefits by neutralizing the B cell activating factor to reduce abnormal B cell survival, and by blocking the type I interferon receptor to inhibit interferon-driven inflammation, improving disease activity, reducing flares, and lowering steroid use (84)
There was two very small phase 1 and phase 2 trials on rectal BPC enemas in the early 2000s from that same Croatian group
Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers
Tired of dull, uneven, tired-looking skin